AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01021852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
Study NCT01021852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to MK-6096
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
Study NCT01634321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
Study NCT01985633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell suspension
Description: About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
Study NCT01985633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
Study NCT01985633 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
Study NCT04017442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative Free Morphine
Description: After delivery of the baby patients will receive via the epidural catheter prior to its removal.
Study NCT04017442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After delivery of the baby patients will receive via the epidural catheter prior to its removal.
Study NCT01879956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Craft Activities
Description: There is no intervention method used to perform the task.
Study NCT01879956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OGI Method
Description: metacognitive approach to assess executive functions.
Study NCT01153191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal saline pressurized irrigation
Description: same
Study NCT01153191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sub-q gentamicin
Description: 2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
Study NCT03408548 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling root planning
Description: Periodontal treatment
Study NCT03408548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling root planning
Description: Periodontal treatment
Study NCT03408548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: two lozenge per day containing Bifidobacterium animalis lactis HN019
Study NCT03408548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two lozenge per day not containing Bifidobacterium animalis lactis HN019
Study NCT02466321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverse/Reverse Shoulder Arthroplasty
Description: Implantation of the Anatomical Shoulder Inverse/Reverse System
Study NCT01238133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01238133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT01238133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01238133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01238133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Ancillary studies
Study NCT01238133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04260828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Daily active drug administered orally for 3 months.
Study NCT04260828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill administered orally for 3 months.
Study NCT00718757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 5 doses given on Days 6-10
Study NCT00718757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
Study NCT00718757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg
Study NCT02952326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XP Endo Finsher as final step of the irrigation protocol
Description: The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
Study NCT02952326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional needle irrigation only
Description: The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
Study NCT01760824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy
Description: Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
Study NCT01760824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Description: Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
Study NCT01760824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple therapy
Description: Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
Study NCT01760824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Description: Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
Study NCT04183699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: MRI-targeted + systematic random prostate biopsy
Study NCT00254293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC Solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Study NCT00254293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC Solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Study NCT00254293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Study NCT03947086 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)- Sham
Description: The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
Study NCT03947086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved.
Study NCT00254293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Study NCT00254293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Study NCT03947086 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved.
Study NCT04048135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection
Study NCT04048135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT00705120 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Irradiation, Total Body
Study NCT00705120 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Study NCT00705120 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporin
Study NCT00705120 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesenchymal Stem Cell Transplantation
Study NCT00705120 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Study NCT02588066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligamentum teres/falciform-plasty
Description: Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
Study NCT03341000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISCSS Device
Description: This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.
Study NCT03286244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus paclitaxel
Description: CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles.
Study NCT04391101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: 400-500ml convalescent plasma
Study NCT01677936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisins
Description: 1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
Study NCT01677936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snacks
Description: 100 calorie snack packs will be administered to the subjects in the snack group
Study NCT03967704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Life quality evaluation
Description: As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss > 2 cm and/or pain.
Study NCT00502229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate, metformin, highly purified urinary FSH
Study NCT00283322 — intervention group
Intervention type: OTHER
Intervention: blood samples (2)
Description: Two blood samples were obtained from patients and tested for heparin antibodies.
Study NCT04127955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior based Physical Activity Intervention
Description: Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial.
Study NCT04316130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uincare Homeplus
Description: Interactive digital healthcare system
Study NCT04316130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Brochure
Study NCT02503475 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Real-Time fMRI
Description: Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements.
Study NCT02503475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT or MBSR
Description: CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
Study NCT02503475 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acupuncture
Description: Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
Study NCT03913897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction methods
Description: The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
Study NCT04053413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
Study NCT02138292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (2mg)/Digoxin (.25mg)
Description: 1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks.
Study NCT03728023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205
Description: SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
Study NCT03728023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose in SAD and once daily for 14 days
Study NCT03150355 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroplasty or open reduction and internal fixation
Description: fixation of proximal femoral fractures or replacement with prosthesis
Study NCT03409991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opening Doors
Description: This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
Study NCT04451187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 1
Description: Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.
Study NCT04451187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 2
Description: Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.
Study NCT04451187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
Study NCT03872362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images
Study NCT01206127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative positioning: Bed rest
Description: Patients in this group should be lying down facing up 2 hours postoperatively
Study NCT02099175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing curative neck irradiation
Description: LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively.
Study NCT04584151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional analgesia
Description: Insertion of bilateral ESP catheters
Study NCT00300274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
Study NCT00300274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil supplied as 500 mg tablets.
Study NCT03915886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-0440
Description: JNJ-0440 tablets will be administered orally.